

Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems



Editor:
M. O. Faruk Khan

Bentham Books

Medicinal Chemistry for Pharmacy Students

(Volume 3)

Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems

Edited by

M. O. Faruk Khan

University of Charleston

School of Pharmacy

Charleston, WV

USA

Medicinal Chemistry for Pharmacy Students

(Volume 3)

Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems

Editor: M. O. Faruk Khan

ISSN (Online): 2589-6989

ISSN (Print): 2589-6997

ISBN (Online): 978-981-5179-72-9

ISBN (Print): 978-981-5179-73-6

ISBN (Paperback): 978-981-5179-74-3

©2024, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2024.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
LIST OF CONTRIBUTORS	iv
CHAPTER 1 DRUGS AFFECTING RENIN-ANGIOTENSIN SYSTEM	1
<i>M. O. Faruk Khan and Karrie Murphy</i>	
HISTORICAL BACKGROUND	1
INTRODUCTORY CONCEPTS	3
The Renin-Angiotensin System (RAS)	3
Angiotensin-Converting Enzyme Inhibitors (ACEIs)	5
Structure of ACE Active Site and Mechanism of Ang I Hydrolysis	6
Inhibition of ACE – The ACEI-ACE Interaction	8
Pharmacophore and SAR Summary of ACEIs	8
<i>SAR Summary</i>	9
The Individual ACEIs and their Structural and Therapeutic Evaluations	10
<i>Sulfhydryl-Containing Inhibitor – Captopril</i>	10
<i>Dicarboxylate Containing Inhibitors</i>	11
<i>Phosphinate Containing Inhibitor - Fosinopril</i>	14
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)	14
The AT1R Binding Pockets	15
Pharmacophore of ARBs and Structure-Activity Relationship	16
<i>SAR Summary</i>	17
The Individual ARBs and their Structural and Therapeutic Evaluations	18
Recalls of the ARBs	22
Therapeutic Considerations of ACEI and ARBs	22
RENIN INHIBITOR ALISKIREN (TEKTURNA®)	23
CASE STUDY	24
DRUG DISCOVERY CASE STUDIES	25
Discovery of ACEIs	25
<i>Teprotide-the First Clue</i>	25
<i>Carboxypeptidase A – the Homology Model</i>	26
<i>Development of Captopril</i>	27
<i>Development of Enalapril and Lisinopril</i>	28
Development of ARBs	28
<i>From Saralasin to Losartan and Eprosartan</i>	28
STUDENT SELF-STUDY GUIDE	30
STUDENT SELF-ASSESSMENT QUESTIONS	31
REFERENCES	36
CHAPTER 2 Ca²⁺ CHANNEL BLOCKERS	40
<i>Taufiq Rahman and M. O. Faruk Khan</i>	
HISTORICAL BACKGROUNDS OF Ca²⁺-CHANNEL BLOCKERS	40
INTRODUCTORY CONCEPTS	41
The Voltage Gated Ca ²⁺ -Channels (VGCCs) and their Clinical Significance	41
Sub-classes of VGCC	44
CALCIUM CHANNEL BLOCKERS	45
The 1,4-Dihydropyridines (DHPs)	46
<i>Structure Activity Relationship (SAR) of DHP Derivatives</i>	46
<i>NO-Releasing Activity of 1,4-Dihydropyridines</i>	50

<i>Individual 1,4-Dihydropyridine Drugs</i>	50
Phenylalkylamines (PAAs)	54
<i>Structure-Activity Relationship of the Phenylalkylamines</i>	55
<i>Verapamil</i>	56
Benzothiazepines (BTZs)	57
<i>Structure-Activity Relationships of Benzothiazepines</i>	57
<i>Diltiazem</i>	58
Diaminopropanol Ethers	59
CLINICAL CASE STUDIES	60
Case 1	60
Case 2	61
Case 3	61
DRUG DISCOVERY CASE STUDIES	61
Discovery of Verapamil	61
Discovery of Nifedipine and its Analogues	62
STUDENT SELF-STUDY GUIDE	62
STUDENT SELF-STUDY QUESTIONS	63
Part I: Multiple Choice Questions.	63
Questions 6 - 8 are Based on the Following Structures:	65
REFERENCES	67
CHAPTER 3 DIURETICS	70
<i>David J. Weldon, Krista G. Brooks and M. O. Faruk Khan</i>	
HISTORICAL PERSPECTIVES	71
INTRODUCTORY CONCEPTS	72
OSMOTIC DIURETICS	74
Mechanism of Action of the Osmotic Diuretics	75
Available Therapeutic Agents (Table 2)	76
CARBONIC ANHYDRASE INHIBITORS	76
Mechanism of Action of CAIs	77
<i>SAR Summary of Sulfonamides as CAIs</i>	77
Available Therapeutic Agents (Tables 3 and 4)	79
THIAZIDE DIURETICS	81
Mechanism of Action of Thiazide Diuretics	81
<i>SAR Summary of Thiazide Diuretics</i>	81
Available Therapeutic Agents (Table 5)	82
LOOP DIURETICS	84
Mechanism of Action of Loop Diuretics	84
<i>SAR Summary of Loop Diuretics</i>	85
Available Therapeutic Agents	85
POTASSIUM-SPARING DIURETICS	87
Aldosterone Antagonists	87
<i>Available Agents</i>	89
Non-Steroidal MRA: Finerenone (Kerendia®)	90
Epithelial Sodium Channel (ENaC) Antagonists	91
Available Agents (Table 8)	92
CASE STUDIES	93
Case 1	93
Case 2	94
Case 3	94
DRUG DISCOVERY CASE STORIES	95

Discovery of Carbonic Anhydrase Inhibitor: Acetazolamide	95
Discovery of the Thiazide Diuretic Chlorothiazide	96
Discovery of Loop Diuretic Furosemide	97
STUDENT SELF-STUDY GUIDE	97
STUDENT SELF-ASSESSMENT QUESTIONS	98
REFERENCES	103

CHAPTER 4 ANTICOAGULANTS, ANTIPLATELETS AND THROMBOLYTIC AGENTS 107

M. O. Faruk Khan and A. R. M. Ruhul Amin

HISTORICAL BACKGROUND	108
INTRODUCTORY CONCEPTS	110
Hemostasis	110
Biochemical Pathway of Clotting	111
Blood Coagulation Risk Factors	112
ANTICOAGULANTS	114
Heparin and Derivatives	114
UFHs and LMWHs	114
<i>Mechanism of Action</i>	116
<i>Adverse Effects, Contraindications, Antidotes and Pharmacokinetics</i>	117
Fondaparinux (Arixtra [®])	118
Warfarin	118
<i>Chemistry, Mechanism of Action, and Therapeutic Uses</i>	118
<i>Pharmacokinetics</i>	120
<i>Monitoring of Warfarin Therapy</i>	121
<i>Food and Drug Interactions</i>	121
DIRECT THROMBIN INHIBITORS (DTIs)	121
Hirudin and its Recombinant Derivatives	122
Argatroban	123
Oral Direct Thrombin Inhibitor: Dabigatran	123
DIRECT FACTOR XA INHIBITORS	124
Rivaroxaban (Xarelto [®])	125
Apixaban (Eliquis [®])	126
Edoxaban (Savaysa [®])	126
Betrixaban (Bevyxxa [®])	127
ANTIPLATELET AGENTS	127
Cyclooxygenase Inhibitor: Aspirin	129
Glycoprotein IIb/IIIa Receptor Blockers	130
<i>Abciximab (ReoPro[®])</i>	130
<i>Eptifibatide (Integrilin[®])</i>	130
<i>Tirofiban (Aggrastat[®])</i>	131
P2Y ₁₂ Receptor Blockers: Clopidogrel, Ticlopidine, Prasugrel, Ticagrelor	131
<i>Thienopyridine Derivatives</i>	132
<i>ADP Analog: Cangrelor (Kengreal[®])</i>	134
<i>Cyclopentyltriazolopyrimidine: Ticagrelor</i>	135
Phosphodiesterase (PDE) Inhibitors	136
<i>Dipyridamole</i>	136
<i>Cilostazol (Pletal[®])</i>	137
<i>Anagrelide (Xagrid[®])</i>	138
PROTEASE ACTIVATED RECEPTOR 1 (PAR-1) ANTAGONIST	139
Vorapaxar (Zontivity [®])	139
THROMBOLYTICS	140

Streptokinase	141
Alteplase	142
Reteplase (Retavase®)	142
Tenecteplase (TNKase®; Metalyse®; Elaxim®)	142
Defibrotide (Defitelio®)	143
ANTIDOTES OF ANTICOAGULANTS AND ANTIPLATELETS	143
Protamine	143
Andexanet Alfa (Andexxa®)	144
Idarucizumab (Praxbind®)	144
Vitamin K	144
PLATELET STIMULATING AGENTS	145
Thrombopoietin Receptor Agonists	145
<i>Eltrombopag (Promacta®)</i>	145
<i>Romiplostim (Nplate®)</i>	147
Antifibrinolytic Agents	147
<i>Tranexamic Acid</i>	147
<i>ε-Aminocaproic Acid (Amicar®)</i>	148
CLINICAL CASE STUDY	148
Case 1	148
Case 2	148
DRUG DISCOVERY CASE STUDY	149
Discovery of Warfarin	149
Discovery of Ticagrelor	150
Discovery of Apixaban	151
STUDENT SELF-STUDY GUIDE	152
STUDENT SELF-ASSESSMENT QUESTIONS	153
Match the drug structures (A-H) with the appropriate names (20-26).	158
REFERENCES	158
CHAPTER 5 ANTIHISTAMINES, PROTON PUMP INHIBITORS AND RELATED DRUGS 160	
<i>M. O. Faruk Khan</i>	
HISTORICAL BACKGROUND	161
INTRODUCTORY CONCEPTS	163
Histamine Receptors	163
Histamine Structural Considerations	165
Histamine Agonists	167
Receptor Structures and Pharmacophore Models of the H1 and H2 Receptors	168
<i>The Histamine H1 Receptor</i>	168
<i>The Histamine H2 Receptor</i>	169
HISTAMINE H1 ANTAGONISTS	170
General Mechanism of Antihistaminic Action	170
General Structure and Classification of Antihistamines	170
Therapeutic Evaluations of Each Class of Antihistamines	172
<i>The General Structure Activity Relationship (SAR)</i>	172
<i>The Aminoalkanes and Aminoalkenes (Propylamines)</i>	173
<i>The Piperazines or Cyclizines</i>	176
<i>The Piperidines</i>	178
<i>The Aminoalkyl Ethers - Ethanolamines and Propanolamines</i>	182
<i>Ethylenediamines</i>	185
<i>Phenothiazines</i>	186
<i>Miscellaneous Antihistamines</i>	187

MAST CELL STABILIZERS	189
Introductory Concepts	189
Chemistry and Therapeutic Evaluation of Chromones as Mast Cell Stabilizers	190
HISTAMINE H2 RECEPTOR ANTAGONISTS	191
Histamine-H2 Receptor Interaction: Mechanism of Action	191
<i>The General Pharmacophore and SAR of Histamine H2R Antagonists</i>	191
Chemistry and Therapeutic Evaluations of Individual H2-Blockers	193
THE H3- AND H4-RECEPTOR ANTAGONISTS	195
PROTON PUMP INHIBITORS (PPIs)	196
The Proton Pump	196
Chemistry and Mechanism of PPIs	197
Therapeutic Evaluation of the PPIs	198
<i>pKa Values of the PPIs</i>	198
<i>Pharmacokinetic Considerations of the PPIs</i>	199
<i>Drug Interaction: Concurrent Use of PPI and Antiplatelet Agent</i>	200
CLINICAL CASE STUDIES	201
Case 1	201
Case 2	202
Case 3	202
DRUG DISCOVERY CASE STUDIES	203
Development of Antihistamines	203
Development of Cimetidine	205
Development of Omeprazole	207
STUDENT SELF-STUDY GUIDE	208
STUDENT SELF-ASSESSMENT QUESTIONS	209
Questions 8 and 9 are Based on Following Structures:	211
REFERENCES	213
CHAPTER 6 DIABETES AND ANTIDIABETIC DRUGS	220
<i>M. O. Faruk Khan</i>	
HISTORICAL BACKGROUND	221
INTRODUCTORY CONCEPTS	225
Clinical Overview, Etiology, Risk Factors and Pathophysiology of Diabetes Mellitus	225
Insulin: Biosynthesis, Metabolism and Receptor Function	227
Drug Induced Diabetes	230
Diabetic Ketoacidosis	231
Hyperglycemic Hyperosmolar Nonketotic Syndrome (HHNS)	231
MANAGEMENT AND TREATMENT OF DIABETES MELLITUS	231
Pharmacological Management of Diabetes	233
<i>Insulin Human and Insulin Analogs</i>	233
<i>Intermediate-acting Insulin Preparation: NPH Insulin</i>	239
<i>Clinical Considerations of the Insulins</i>	240
<i>Sulfonylureas</i>	241
<i>Meglitinides</i>	250
<i>Biguanides: Metformin</i>	253
<i>PPAR Agonists: Thiazolidinediones</i>	255
<i>Alpha Glucosidase Inhibitor: Acarbose (Precose®)</i>	258
<i>GLP-1 Agonists</i>	259
<i>DPP-4 inhibitors or Gliptins</i>	265
<i>GLP-1 vs DPP-4 Inhibitors</i>	269
<i>Amylin Agonist: Pramlintide (Symlin®)</i>	270

<i>SGLT2 Inhibitors, the Gliflozins</i>	270
Imeglimin (Twymeeq®) – A Novel Class of Investigational Drug	274
CLINICAL CASE STUDIES	275
DRUG DISCOVERY CASE STUDIES	277
Discovery of Dapagliflozin	277
Discovery of Pioglitazone	278
Discovery of Metformin	279
Discovery of Tolbutamide	279
STUDENT SELF-STUDY GUIDE	280
STUDENT SELF-ASSESSMENT QUESTIONS	280
Part III: Matching Questions:	290
REFERENCES	291
CHAPTER 7 HORMONEAL THERAPY	295
<i>M. O. Faruk Khan and Chelsey Llayton</i>	
HISTORICAL PERSPECTIVE	296
Hormone Replacement Therapy	296
Oral Contraceptives	297
Androgen Replacement Therapy	298
Transgender Healthcare	298
INTRODUCTORY CONCEPTS	299
ORAL CONTRACEPTIVES AND HORMONE REPLACEMENT THERAPY	302
Endogenous Estrogens	302
<i>Biological Actions of Estrogens</i>	305
<i>Mechanism of Action of Estrogens</i>	306
<i>Pharmacokinetics of Estrogens</i>	307
Other Estrogens and Stilbenes	307
Safety of Estrogen Therapy	310
Progestogens	310
<i>Progesterone</i>	311
<i>Hydroxyprogesterone Caproate</i>	313
<i>Megestrol</i>	313
<i>Medroxyprogesterone</i>	313
<i>Chlormadinone</i>	313
<i>Drospirenone</i>	314
<i>Norethindrone</i>	315
<i>Ethinodiol Diacetate</i>	316
<i>Levonorgestrel</i>	316
<i>Desogestrel</i>	316
<i>Norgestimate</i>	316
Progesterone Receptor Antagonists	317
<i>Mifepristone</i>	317
<i>Ulipristal</i>	317
FERTILITY AGENTS	317
Clinical Gonadotropins	318
<i>Follitropin Alfa and Beta</i>	318
<i>Urofollitropin</i>	318
<i>Lutropin Alfa</i>	319
<i>Menotropins</i>	319
Gonadotropin Agonists	319
<i>Leuprolide</i>	319

<i>Goserelin</i>	320
<i>Nafarelin</i>	320
Gonadotropin Antagonists	320
<i>Abarelix (Plenaxis®)</i>	321
<i>Cetrorelix (Cetrotide®)</i>	322
<i>Degarelix (Firmagon®)</i>	322
<i>Ganirelix (Antagon®)</i>	322
<i>Elagolix (Orilissa®)</i>	322
Nonsteroidal Infertility Treating Agent: Clomifene	322
Safety of Gonadotropins	323
ANDROGENIC AND ANABOLIC AGENTS	323
Androgenic Agents	324
<i>Testosterone and Related Physiological Androgens</i>	324
<i>Methyltestosterone</i>	325
<i>Fluoxymesterone</i>	326
<i>Danazol</i>	326
Anabolic Agents	326
Other Agents	328
GROWTH HORMONE	328
Secretion and Function of Growth Hormone	328
Clinical Significance of GH	330
Therapeutic Use of GH	330
<i>Replacement Therapy</i>	330
<i>Treat Short Stature</i>	330
Side Effects	330
THYROID HORMONES AND ANTI-THYROID AGENTS	331
Introduction to Thyroid Hormones (THs)	331
Biosynthesis of T4 and T3	331
Physiological Role of THs	332
<i>Effects on Metabolism</i>	333
<i>Effects on Oxygen Carriage and Consumption</i>	333
<i>Effects on the Cardiovascular System</i>	333
<i>Effects on Growth and Tissue Development</i>	334
<i>Effects on the Nervous System</i>	334
Pharmacokinetics of THs	334
Hypothyroidism and Hyperthyroidism	334
Hypothyroidism Treatment	335
<i>Levothyroxine Sodium (Synthroid®, Unithroid®, Levothroid®, Levoxyl®)</i>	335
Hyperthyroidism Treatment/Anti-Thyroid Agents	335
<i>Methimazole</i>	335
Propylthiouracil	336
CALCITONIN AND PARATHYROID HORMONE	338
Calcitonin	338
Parathyroid Hormone	338
Vitamin D and Hyperparathyroidism	339
CLINICAL CASE STUDIES	339
Case 1	339
Case 2	340
Case 3	341
DRUG DISCOVERY CASE STUDIES	341
Discovery of Synthetic Estrogens: Diethylstilbestrol	341

Discovery of Antiprogestin: Mifepristone	343
STUDENT SELF-STUDY GUIDE	343
STUDENT SELF-ASSESSMENT QUESTIONS	344
REFERENCES	349
CHAPTER 8 THE PROSTANOIDS	353
<i>M. O. Faruk Khan and Karrie Murphy</i>	
HISTORICAL BACKGROUND	353
INTRODUCTORY CONCEPTS	354
Eicosanoids: Structure and Function	354
Eicosanoids: Biosynthesis	356
Prostanoid Receptors	358
Prostacyclin and Prostaglandin Analogs	359
PROSTAGLANDIN ANALOGS USED IN GLAUCOMA	359
Latanoprost	359
<i>Latanoprost Isopropyl Ester (Xalatan®)</i>	359
<i>Latanoprostene Bunod (Vyzulta®)</i>	361
Bimatoprost (Lumigan® and Durysta®)	361
Travoprost (Travatan®)	362
Unoprostone	363
Tafluprost	363
Clinical Consideration of the Prostaglandin Analogs Used for Glaucoma	363
OTHER PROSTAGLANDIN ANALOGS	364
Misoprostol (Cytotec®)	364
Dinoprostone (Preptidil®)	365
Carboprost	365
Alprostadiol	365
PROSTACYCLINS	366
Epoprostenol (Veletri®; Flolan®)	366
Iloprost (Ilomedine®; Ventavis®)	366
Teprostinil (Orenitram®, Tyvaso®, Remodulin®)	367
Selexipag (Uptravi®)	368
Clinical Consideration for PGI ₂ Analogs in PAH	368
LEUKOTRIENE ANALOGS	369
Montelukast (Singulair®)	369
Zafirlukast (Accolate®)	369
CLINICAL CASE STUDY	370
Case 1	370
Case 2	371
DRUG DISCOVERY CASE STUDY	372
Discovery of Zafirlukast	372
Discovery of Latanoprost	373
STUDENT SELF-STUDY GUIDE	374
STUDENT SELF-ASSESSMENT QUESTIONS	375
REFERENCES	380
SUBJECT INDEX	5: 2

FOREWORD

For a pharmacist, medicinal chemistry education is critical to developing an adequate knowledge base and critical thinking skills. In this *eBook*, the fundamental principles of medicinal chemistry including the functional groups occurring in medicinal agents, the acidity and basicity of drugs, and their water and lipid solubility as well as drug-receptor interactions are described. The physicochemical principles, isosterism, and spatial characteristics of drugs are prerequisites to understanding drug pharmacodynamics. Another important aspect that is crucial to comprehending the mechanism of drug action is the knowledge of important biosynthetic pathways that are frequently encountered in pharmaceutical interventions; a chapter has been devoted to this important aspect in this first volume. In this book, a comprehensive approach has been taken to explain the phases of drug metabolism, modifications of drug chemical structures, and their effects on drug pharmacokinetics, safety, and efficacy.

It is apparent that the authors have taken into consideration the integrated aspect of PharmD curricula while developing the contents. The standout feature of this *eBook* series is its layout, which includes 4 volumes in three distinct areas - the fundamental concepts, detailed structure-activity relationships of different drug classes, and recent developments in the area of medicinal chemistry and drug discovery. It offers students the opportunity to learn the principles of drug action in a stepwise manner. The case studies, student's self-study guide, and self-assessment at the end of each chapter are unique features of this book that would be beneficial to both students and instructors. Although there are several medicinal chemistry textbooks available on the market, to my understanding this is the first textbook of its kind focusing on the integrated aspects of PharmD curricula.

As a pharmacy educator, leader, journal editor, and an expert in pharmacy curriculum, I am pleased to testify and endorse this *eBook* to pharmacy educators, and learners as one of the most useful resources in medicinal chemistry. Based on my pedagogical research and assessment of student learning, it is my understanding that this book takes a student-friendly approach that incorporates appropriate illustrative diagrams and study guides as well as self-assessments. In my early years as a student in the pharmacy, I found medicinal chemistry as a challenging subject area. The inclusion of clinical and management focuses in the modern PharmD curriculum left the students with limited time available to grasp all the basic concepts which made it more challenging for them to manage the old hard-core science-driven medicinal chemistry courses. This *eBook* series brings those memories of my early years as a pharmacy student and the evolution of pharmacy education, and gives me the confidence that it will pave the way for future medicinal chemistry education for pharmacists and other health professionals.

Gayle Brazeau

Professor, Marshall University School of Pharmacy
Editor, American Journal of Pharmaceutical Education
Huntington, WV
USA

PREFACE

This is the third volume of the 4-volume eBook series, “*Medicinal Chemistry for Pharmacy Students*”. The primary objective of this e-Book series is to educate PharmD students in the area of medicinal chemistry and serve as a reference guide to pharmacists on aspects of the chemical basis of drug action. A thorough discussion of key physicochemical parameters of therapeutic agents and how they affect the biochemical, pharmacological, pharmacokinetic processes and clinical use of these agents is the primary focus of the whole book. The rationale for putting together an e-Book of this nature is to equip PharmD students with the scientific basis to competently evaluate, recommend and counsel patients and healthcare professionals regarding the safe, appropriate, and cost-effective use of medications.

This third volume of the series is comprised of 8 chapters focusing on a comprehensive account of medicinal chemistry of drugs affecting the cardiovascular and endocrine systems. It provides the mechanism of drug action, detailed structure-activity relationships and metabolism as well as the clinical significance of drugs affecting the cardiovascular and endocrine system to give the knowledge base for pharmacists.

Chapter 1 provides a comprehensive account of the medicinal chemistry of drugs affecting the renin-angiotensin system (RAS). This chapter includes pathophysiologic principles, mechanism of action, structure-activity relationships (SAR) and metabolism of drugs affecting RAS including enzymes and hormones and their roles in blood pressure, structures, binding, and chemistry and SAR of the antagonists involved in RAS such as the angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) and renin inhibitors. It also discusses the clinical significance and therapeutic evaluations of these classes of drugs by solving case studies as well as the discovery process of ACEIs and ARBs.

Chapter 2 is a comprehensive account of the medicinal chemistry of antihypertensive drugs, Ca²⁺-channel blockers (CCBs). It details the pathophysiologic principles, mechanism of drug action, SAR, classifications, and their clinical significance.

Chapter 3 focuses on the medicinal chemistry of the diuretic agents. It provides a detailed account of the pathophysiologic principles of diuretics, the mechanism of drug action and the SAR of these drugs. The chemical principles and classification of diuretics, their metabolism and pharmacokinetic parameters, and the clinical significance as well as safety parameters of these drugs have been clearly delineated.

Chapter 4 is a comprehensive account of the medicinal chemistry of the anticoagulants, antiplatelets and thrombolytic agents and their relatives – their pathophysiologic principles, mechanism of action, SAR and metabolism. Topics include the physiology and pathophysiology of clotting, major classes of anticoagulant drugs and their structures and binding, distinctions among drugs used as antiplatelets, anticoagulants, and fibrinolytic agents and delineation of the clinical significance, therapeutic evaluations and discovery story of these classes of drugs.

Chapter 5 is a comprehensive account of the medicinal chemistry of antihistamines, H2 receptor (H2R) blockers, H3 receptor (H3R) blockers, and proton pump inhibitors (PPIs). It provides the pathophysiologic principles, mechanism of drug action, and detailed SAR of the drugs in these classes. Topics include a concise account of the physicochemical properties of histamine and histamine receptors, chemical classes of antihistamines, H2R and H3R antagonists, the distinction between sedating and non-sedating antihistamines, as well as the

first generation, second generation, and third generation antihistamines. It also discusses the structural features of cromolyn and related mast cell stabilizers as well as the proton pump inhibitors including their development, mechanism of action, and structural and physicochemical features.

Chapter 6 is a comprehensive account of diabetes and the medicinal chemistry of antidiabetic drugs. It discusses the physicochemical principles, mechanism of action, SAR, and metabolism of the antidiabetic drugs. The clinical features of diabetes and differentiation between type I and type II diabetes, various risk factors and corresponding mechanisms responsible for the development of diabetes and pathophysiologic mechanisms responsible for the clinical features of diabetes have also been discussed. A review of biosynthesis of insulin, its metabolic outcomes, regulation of insulin secretion, and insulin signaling have been explained. This chapter has classified all the injectable and oral antidiabetic drugs and provided their clinical significance as well.

Chapter 7 is a comprehensive account of the medicinal chemistry of hormonal therapy. It provides the physicochemical principles, mechanism of drug action, SAR, and drug metabolism of the hormonal agents. This chapter discusses in detail hormone replacement therapy (HRT), androgen replacement therapy (ART), oral contraceptive pills and gender-affirming hormone therapy. It also provides a detailed understanding of thyroid hormones and their clinical significance.

Chapter 8 provides a comprehensive account of the medicinal chemistry of drugs arising from structural modifications of prostanoids, which are naturally occurring eicosanoids. These drugs are used for a variety of disease states including but not limited to glaucoma, pulmonary arterial hypertension, and peptic ulcers. This chapter provides the pathophysiologic principles, mechanism of drug action, and SAR of these agents with their clinical significance.

The chapters in this volume are designed to guide the reader to review, integrate, and apply principles of medicinal chemistry to drug action of therapeutic agents. All concepts are illustrated with diagrams or figures, with the keywords highlighted, bulleted or numbered. Wherever needed, special boxes and case studies are included. In addition, each chapter is reinforced with student's self-study guides and self-assessment questions. Special notations are highlighted using call-out boxes for visual effect. Tables and figures are used to augment the text as needed.

We would like to express our sincere gratitude to the contributing authors for their time and effort in completing this volume. We would also like to thank Bentham Science Publishers, particularly Ms. Asma Ahmed (Manager Publications) and Mr. Mahmood Alam (Director Publications) for their support. We are confident that this volume of the eBook series will guide students and educators of pharmacy and related health professions worldwide.

M. O. Faruk Khan
University of Charleston
School of Pharmacy
Charleston, WV
USA

List of Contributors

- A. R. M. Ruhul Amin** School of Pharmacy, Marshall University, Huntington, WV, USA
- Chelsey Llayton** University of Charleston, School of Pharmacy, Charleston, WV, USA
- David J. Weldon** School of Pharmacy, William Carey University, Biloxi, Mississippi, USA
- Karrie Murphy** University of Charleston, School of Pharmacy, Charleston, WV, USA
- Krista G. Brooks** Southwestern Oklahoma State University College of Pharmacy, Weatherford, OK, USA
- M. O. Faruk Khan** University of Charleston, School of Pharmacy, Charleston, WV, USA
- Taufiq Rahman** Department of Pharmacology, University of Cambridge, UK

CHAPTER 1

Drugs Affecting Renin-Angiotensin System

M. O. Faruk Khan^{1,*} and Karrie Murphy¹

¹ University of Charleston, School of Pharmacy, Charleston, WV, USA

Abstract: This chapter presents a comprehensive account of the medicinal chemistry of drugs affecting the renin-angiotensin system (RAS). It provides the mechanism of drug action and details structure-activity relationships (SAR) of the drugs affecting RAS to give the knowledge base for pharmacists. After studying this chapter, students will be able to:

- Describe the historical background the RAS and drugs acting on this system.
- Explain RAS enzymes and hormones and their roles in blood pressure.
- Classify drugs acting on the RAS and their structures and binding.
- Discuss in detail the chemistry and SAR of the antagonists involved in RAS including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) and renin inhibitors.
- Delineate the clinical significance and therapeutic evaluations of these classes of drugs by solving case studies.
- Explain the discovery process of ACEIs and ARBs.

Keywords: ACE, ACEIs, ARBs, Drug receptor interaction, Renin inhibitor, RAS, Structure-activity relationship.

HISTORICAL BACKGROUND

As early as 1898, renin's role in increasing blood pressure was suggested based on the observation that the injection of kidney extracts dramatically increased rabbit's blood pressure [1]. In the 1930s, a pathologist named Harry Goldblatt discovered a vasoconstricting agent (which later appeared to be renin) secreted by the kidneys responsible for increasing blood pressure [2]. In 1939, it was concluded that renin is an enzyme which catalyzes the formation of angiotensin (Ang) [3]. Decades later, two forms of Ang, Ang I and Ang II, were identified.

* Corresponding author M. O. Faruk Khan: University of Charleston, School of Pharmacy, Charleston, WV, USA; Tel: 304-357-4860; E-mail: mdomarkhan@ucwv.edu

A zinc metallopeptidase, angiotensin converting enzyme (ACE), was discovered in 1954 from equine plasma and purified in 1956 [4, 5]. It is now known that renin first converts angiotensinogen (a 14-amino acid peptide) into Ang I (a decapeptide), which is then converted by ACE into Angiotensin II (Ang II, an octapeptide; Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) that causes vasoconstriction and hypertension [6].

In 1965, a Brazilian scientist, Sérgio Henrique Ferreira, reported the presence of a bradykinin potentiating factor (BPF) in the venom of a South American pit viper *Bothrops jararaca* [7], then he moved to the laboratory of Sir John Vane in London, UK for further research. Ng and Vane in 1967 showed that Ang I is quickly converted into Ang II by ACE in the pulmonary circulation and lung. The finding that BPF inhibits the conversion of Ang I into Ang II led to believe that bradykinin also disappears in the lung by the action of ACE [8 - 10].

Vane convinced Bristol Myers Squibb Pharmaceutical Company to work on the project of snake venom and started fractional analysis of the BPF. They isolated a nonapeptide, teprotide (SQ 20,881), to be the most potent ACE inhibitor (ACEI) and antihypertensive agent *in vivo* (see later in drug discovery case studies) [11]. They purified a few more peptides: all of which were found to be ACEIs Table (1) [12]. As a peptide, teprotide is orally ineffective. In search of an orally effective drug, they investigated about 2000 non-peptides without any success. In the early 1970s, they started using the other mechanistically similar, but widely studied enzyme carboxypeptidase A and its 3D-structure of the active site to design ACEI and successfully launched captopril as the first orally active ACEI in 1975, which was approved by US Food and Drug Administration (FDA) in 1981 (see later in drug discovery case studies) [13].

Table 1. The peptide inhibitors of ace isolated from snake venom.

Peptide Structure	IC ₅₀ (µg/mol) ^a
Glu-Trp-Pro-Arg-Pro-Lys-Phe-Ala-Pro-OH	0.05
Glu-Lys-Trp-Ala-Pro-OH	0.05
Glu-Phe-Ala-Pro-OH	2.7
Phe-Ala-Pro-OH	1.4
Ala-Pro-OH	50

^aIC₅₀ is the concentration of peptide needed to inhibit the activity of ACE by 50%.

The first Ang II receptor type 1 (AT₁R) was identified during the 1970s and was cloned in the 1990s. The AT₂R was identified during the early 1980s and cloned in the early 1990s [14] although the existence of different forms of ATRs was suggested in 1974 [15] by Papadimitriou and Worcel. Other ATRs including AT₃R and AT₄R have also been recognized to date, all of which are G-protein

coupled 7-transmembrane (7-TM) containing receptors. Only AT₁R and AT₂R are clinically significant [16]. AT₁R mediates most of the functions of Ang II while AT₂R contributes to the regulation of blood pressure and renal functions. This discovery triggered the development of AT₁R blockers (ARBs). Saralasin, a peptide analog of Ang II, was found to be a potent ARB but lacked oral bioavailability [17]. Takeda, a Japanese company, in the early 1980s, tested a series of compounds to find a lead and developed losartan as the first clinically useful, orally active, potent and selective nonpeptide ARB by DuPont chemists [18].

Another drug acting on the renin-angiotensin system (RAS) is aliskiren, an orally effective, nonpeptide, low-molecular-weight renin inhibitor. It was co-developed by the Swiss pharmaceutical companies Novartis and Speedel through a combination of molecular modeling techniques and crystal structure elucidation of renin and the renin-drug complex [19, 20]. Aliskiren was approved for clinical use in the USA in 2007 for the treatment of primary hypertension.

Angiotensin inhibition has also been combined with neprilysin inhibition for the treatment of chronic heart failure. This angiotensin receptor neprilysin inhibitor (ARNI) is a combination of valsartan (an ARB) and sacubitril, a neprilysin inhibitor approved in July 2015 by the FDA [21, 22]. The development of this drug was prompted by the need to inhibit neprilysin and RAS concurrently. Neprilysin inhibition alone can enhance the beneficial response of natriuretic peptides released in heart failure but can result in the counteractive activation of the RAS by increasing angiotensin II. Although both ACEIs and ARBs inhibit RAS, only ARBs are recommended to be utilized with neprilysin inhibitors. Prior to valsartan/sacubitril approval, a drug containing an ACEI and a neprilysin inhibitor called omapatrilat was developed. This drug was never marketed due to the increased incidences of angioedema observed in clinical trials [23].

Today, drugs affecting the RAS comprise a large class of clinical agents and many of these frequently are among the top 200 medications dispensed. Those included in the last few years are shown in Fig. (1).

INTRODUCTORY CONCEPTS

The Renin-Angiotensin System (RAS)

The RAS regulates blood pressure and fluid balance. Renin, secreted by kidneys when blood volume or blood pressure is low, stimulates the biosynthesis of Ang I from angiotensinogen. ACE in the lung and pulmonary circulations then converts Ang I to Ang II, which causes vasoconstriction resulting in increased blood pressure. Ang II also stimulates the secretion of aldosterone which causes

Ca²⁺ Channel Blockers

Taufiq Rahman¹ and M. O. Faruk Khan^{2,*}

¹ Department of Pharmacology, University of Cambridge, UK

² University of Charleston, School of Pharmacy, Charleston, WV, USA

Abstract: This chapter is a comprehensive account of the medicinal chemistry of antihypertensive drugs, Ca²⁺-channel blockers (CCBs). It provides the mechanism of drug action and detailed structure-activity relationships (SAR) of the CCBs to give the knowledge base for pharmacists. After studying this chapter, students will be able to:

- Comprehend the historical background of the CCBs.
- Classify different types of voltage-gated Ca²⁺ channels (VGCCs) and their clinical significance.
- Explain CCBs and their clinical significance.
- Describe the mechanisms of action of CCBs at the molecular level including their binding modes against the VGCCs.
- Describe the SAR of the different classes of CCBs.
- Delineate clinical significance and therapeutic evaluations of these classes of drugs by solving case studies.
- Articulate the discovery process of a few CCBs.

Keywords: Benzothiazepines (BTZs), Ca²⁺-channels, CCBs, Drug-receptor interaction, Dihydropyridines (DHPs), Dihydropyridine receptors (DHPR), Diaminopropanol ethers, Phenylalkylamines (PAAs), Structure-activity relationship (SAR), VGCC.

HISTORICAL BACKGROUND OF CA²⁺-CHANNEL BLOCKERS

Voltage-gated Ca²⁺-channels (VGCCs) are crucial for the normal as well as abnormal physiological scenarios associated with neuronal, neurosecretory and muscle cells. The latter express VGCCs in their plasma membrane – a feature that

* Corresponding author M. O. Faruk Khan: University of Charleston, School of Pharmacy, Charleston, WV, USA; Tel: 304-357-4860; E-mail: mdomarkhan@ucwv.edu

can be used to categorize these cells as 'excitable' [1]. These channels were first identified in crustacean muscle by Paul Fatt and Bernard Katz who observed that these muscles retained the ability of generating action potential even in the absence of any Na^+ in their bathing medium [2]. Fatt and colleagues further investigated the significance of this observation [3]. Later, Hagiwara and Byerly pursued an in-depth characterization of the currents in various invertebrate tissues [4]. Work on mammalian VGCCs began later and progressed in parallel with the invertebrate VGCCs [5]. By now, it is well established that VGCCs are present in the plasma membrane of all excitable cells including muscle, neurons and exocrine glands where they play a critical role in generating action potential and thereby excitation-contraction as well as excitation-secretion coupling [1]. However, they can also be expressed in low levels in non-excitable cells such as immune cells, but their role associated with such non-canonical distribution is yet to be known [5].

The voltage-gated Ca^{2+} -channel blockers (CCBs) were originally synthesized with the intention of developing some selective inhibitors of the voltage-gated potassium channels. Albrecht Fleckenstein and his colleagues at the University of Freiburg (Germany) first showed that prenylamine and verapamil resulted in electromechanical uncoupling in the heart in a way that mimicked the consequences of removing Ca^{2+} from extracellular solution and such effect could be reversed by increasing intracellular Ca^{2+} concentration [6]. Some diphenylpiperazine derivatives such as cinnarizine and flunarizine were reported by Theophile Godfraind and his colleagues to exhibit similar uncoupling of excitation-contraction in vascular smooth muscle [7, 8]. These initial observations prompted further research into the field and eventually led to the development of structurally diverse, second-generation drugs, including diltiazem and nifedipine (and various other 'dipines'), capable of inhibiting these channels. Up until now, all the official drugs that are known to be inhibitors of VGCCs primarily target the **L-type channels** (see later in next section). Although a growing number of studies indicate that VGCCs other than the L-type channels may also be implicated in some pathophysiological conditions, the development of selective antagonists or blockers of these channels remains investigational. Today, a large number of CCBs frequently occur in the top 200 drugs' list Fig. (1).

INTRODUCTORY CONCEPTS

The Voltage Gated Ca^{2+} -Channels (VGCCs) and their Clinical Significance

Calcium is a universal and versatile second messenger, regulating almost every aspect of cellular life [9]. One of the most common ways cells respond to various extracellular stimuli from hormones, growth factors and neurotransmitters is by

transiently increasing the cytosolic free Ca^{2+} concentration from a basal, resting level ($\sim 100\text{-}300\text{nM}$ to $\sim 1\mu\text{M}$). This elevated cytosolic free Ca^{2+} is then sensed by numerous cellular targets and effector proteins to regulate a diverse array of processes such as fertilization, cell growth and differentiation, muscle contraction, exocytosis, synaptic plasticity, transcriptional regulation and apoptosis [9]. Cells derive the 'extra' Ca^{2+} for signaling purposes both from the internal stores (*e.g.*, endoplasmic and sarcoplasmic reticulum, mitochondria, lysosome, nucleoplasm *etc.*) as well as extracellular space. In both cases, Ca^{2+} flows into cytosol down its concentration gradient through Ca^{2+} permeable pores of various ion channels expressed in the plasma membrane as well as the membranes of intracellular organelles that store Ca^{2+} . Opening of these channels is precisely regulated and triggered either by ligand binding or changes in membrane potential (typically depolarization). Members of the latter group, widely known as the VGCC family and often represented as Ca_v channels [10], have been the major therapeutic targets against diseases involving primarily the cardiovascular and to a lesser extent, the nervous system. Therefore, the present chapter will focus on inhibitors of VGCCs as an important therapeutic class.




Fig. (1). Ca^{2+} -channel blockers frequently occurring in top 200 drug list.

Diuretics

David J. Weldon¹, Krista G. Brooks² and M. O. Faruk Khan^{3,*}

¹ School of Pharmacy, William Carey University, Biloxi, Mississippi, USA

² Southwestern Oklahoma State University College of Pharmacy, Weatherford, OK, USA

³ University of Charleston, School of Pharmacy, Charleston, WV, USA

Abstract: This chapter is a comprehensive account of the medicinal chemistry of diuretic agents. It provides the mechanism of drug action and details the structure-activity relationships (SAR) of these drugs to provide a knowledge base for pharmacists. After studying this chapter, students will be able to:

- Identify the chemical classification to which a diuretic agent or therapeutic belongs based on drug structure.
- Evaluate the chemical principles of different classes of diuretics.
- Compare and contrast the potency, onset, and duration of action of the diuretic agents.
- Identify chemical metabolites of the diuretics that increase the risk of nephron and hepatotoxicity.
- Select an appropriate diuretic agent based on patient-specific symptoms of hypertension or other problems.
- Rationalize the clinical application of all diuretic drug classes.
- Communicate the chemical rationale for a diuretic to health professionals.
- Delineate the clinical significance and therapeutic evaluations of these classes of drugs by solving case studies.
- Identify the discovery process of selected diuretic agents.

Keywords: Carbonic anhydrase inhibitor (CAI), Drug receptor interaction, Loop diuretics, Nephron, Osmotic diuretics, Potassium sparing diuretics, Sulfonamides, Structure activity relationship, Thiazide diuretics.

* Corresponding author M. O. Faruk Khan: University of Charleston, School of Pharmacy, Charleston, WV, USA; Tel: 304-357-4860; E-mail: mdomarkhan@ucwv.edu

HISTORICAL PERSPECTIVES

The sufferings and agonies from excess body fluid have been a matter of medical concern since the earliest days of recorded history. Egyptian concoctions for “causing urination” or “expelling excess fluid from the body and heart” were recorded in the Hearst Medical Papyrus in 1550 BC. Pharaonic medicine for these purposes was guided by religious bindings and was composed of complex mixtures of plants and minerals incorporated into beer and honey. The Greek medicines took a rational and secular approach that was laborious in the sense that patients had to consume dry and acrid substances to increase excretion. Hippocrates' (460-377 B.C.E.) recommendations for the treatment of dropsy (edema) were sweating, catharsis, and bleeding, which remained a mainstay until the 20th century when clinically effective diuretics were developed [1].

The manuscript, Dioscorides' *De Materia Medica* (40-90 C.E.), recognized as the supreme authority on medicinal substances for over 1500 years, codified the diuretic properties of several plants including juniper, radishes, cassia, cinnamon, dill, wormwood, periwinkle and squill. The boiled bulb of squill (*Scilla siberica*), a coastal Mediterranean plant, flavored with vinegar or honey, was recommended by Romans, Celsus, and Pliny as a diuretic, and remained the mainstay in diuretic treatment until the 16th century [1 - 3]. In the next century, an extract of the broom plant became a favorite diuretic treatment and remained in use until the 1920s [4, 5].

In the 16th century, Paracelsus began to march away from herbals and became a key figure in the history of diuretics. He refined the concept of the body as a chemical process and pioneered the use of calomel (mercurous chloride) as a diuretic [6]. Later in the 20th century, organic mercurials, as well as other salts including potassium nitrate, potassium acetate, and potassium citrate, were introduced in widespread use as diuretics [5, 7]. An expert botanist, William Withering, introduced digitalis (*Digitalis purpurea*) as a diuretic agent in 1785 to relieve dropsy. Digitalis was among the first class of diuretics during that time [8].

With the exception of digitalis and caffeine, most of the diuretics used today were developed after World War I. By the time World War II started, only four drugs were accepted as effective agents to increase urine flow: caffeine, digitalis, mercury, and acidifying agents. Caffeine was considered a mild diuretic, digitalis was effective only in heart failure, mercury was potentially a toxic choice, and the acidifying agents' efficacies were questionable [1].

In the early to mid 1900s, John Peters, Alfred N. Richards, Homer Smith, and their associates provided insight into renal physiology and the role of the kidney in the production of urine. This advancement in knowledge led to the subsequent

understanding of the mechanisms underlying diuretic therapy. In 1940, Thaddeus Mann and David Keillin of the University of Cambridge discovered that sulfonamides inhibit carbonic anhydrase (CA), and two years later, Rudolf Hober suggested that this effect accounted for the increased excretion of sodium bicarbonate and more production of urine. In 1949, Boston physician William Schwartz introduced sulfanilamide as an oral diuretic agent but patients required a large dose for an appreciable diuretic effect, which was toxic [1, 9].

These discoveries, together with the understanding of the role of the kidney in diuresis and the increased understanding of organic and molecular chemistry, launched the modern era of diuretics. The pharmaceutical industry became involved directly in the development of new and more potent agents. In 1952, Richard Roblin (Lederle Division of the American Cyanamid Company) and James Clapp developed acetazolamide as a potent CAI and clinically effective diuretic agent. Chlorothiazide, the first thiazide diuretic developed by Merck, was reported in 1957. It was introduced in Australia around 1958 as an injectable and soon after as a tablet. In 1962, Hoechst introduced the modern loop diuretic, furosemide, which could be taken orally or injected, and did not seriously affect blood pressure. Ten years later, Researchers of Burinex Leo Pharma introduced a more potent loop diuretic, bumetanide, and once the patent of furosemide expired, Hoechst Pharma introduced its analog piretanide [1, 9]. Today, a large number of diuretics are in the top 200 drug list Fig. (1).

INTRODUCTORY CONCEPTS

Diuresis is the excretion of water from the body in the form of urine. Diuretics are compounds that enhance diuresis due to increased urine flow rate. The net result is lower fluid volume in the circulatory system making diuretics useful in a number of medical conditions including hypertension and primary or secondary edema (from cirrhosis, congestive heart failure, *etc.*). Many diuretics are designed to work in the nephron of the kidney and prevent reabsorption of sodium from the nephron tubule into the circulatory system. The theory is that if more sodium stays in the urine as it is forming in the nephron, then natural osmotic control will also sequester more water in the urine leading to more urine and less water reabsorption. Diuretic drugs not only affect sodium reabsorption, but also the reabsorption and excretion of many electrolytes, such as potassium and calcium. The complicated nature of urine formation in the nephron leads to increases in some electrolytes and decreases in others and is responsible for most of the side effects associated with diuretics shown in Table (1).

CHAPTER 4**Anticoagulants, Antiplatelets and Thrombolytic Agents****M. O. Faruk Khan^{1,*} and A. R. M. Ruhul Amin²**¹ *University of Charleston, School of Pharmacy, Charleston, WV, USA*² *School of Pharmacy, Marshall University, Huntington, WV, USA*

Abstract: This chapter is a comprehensive account of the medicinal chemistry of anticoagulants, antiplatelets and thrombolytic agents and related drugs. It provides the mechanism of drug action and detailed structure-activity relationship (SAR) of the drugs affecting in these clinical areas to give the knowledge base for pharmacists. After studying this chapter, students will be able to:

- Describe the historical background of the anticoagulants, antiplatelets and thrombolytic agents and related drugs.
- Describe the mechanism of action, pharmacokinetics (PK), and adverse drug reaction (ADR) of the anticoagulants, antiplatelets and thrombolytic agents.
- Explain the physiology and pathophysiology of clotting cascades and identify the components of a blood clot.
- Classify major anticoagulant drugs and their structures and binding.
- Discuss in detail the chemistry and SAR of these drugs.
- Distinguish among drugs used as antiplatelets, anticoagulants and fibrinolytic agents.
- Delineate the clinical significance and therapeutic evaluations of these classes of drugs by solving case studies.
- Explain the discovery process of a few specific drugs in these classes.

Keywords: Anticoagulant, Antiplatelet, Antithrombin, Direct thrombin inhibitor (DTI), Fibrinolytic, Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors, Heparin, Low molecular weight heparin (LMWH), Non-vitamin K antagonist oral anticoagulants (NOACs), P2Y₁₂ receptor antagonists, Pulmonary embolism (PE),

* **Corresponding author M. O. Faruk Khan:** University of Charleston, School of Pharmacy, Charleston, WV, USA; E-mail: mdomarkhan@ucwv.edu


Phosphodiesterase (PDE) inhibitors, PAR-1 antagonists, Thrombolytic, Unfractionated heparin (UFH), Venous thromboembolism (VTE), Vitamin K reductase (VKOR), Xa inhibitors.

HISTORICAL BACKGROUND

The discovery and clinical application of heparin and warfarin for the prophylaxis and treatment of VTE 100 years ago set the milestone for anticoagulant therapy. In 1916, a medical student Jay McLean working under the mentorship of William Henry Howell at Johns Hopkins Medical School in Baltimore, Maryland, USA, extracted fat-soluble compounds with anticoagulant properties *in vitro* from dog liver. After McLean left Howell's lab, Howell continued the work on anticoagulants with another medical student L. Emmett Holt Jr., and in 1918, they isolated another fat-soluble anticoagulant. Since isolated from the liver, Howell coined the name 'heparin' for all these anticoagulants (Greek for 'liver'). Between 1922 and 1926, Howell developed and refined protocols for extracting water-soluble polysaccharide anticoagulant, which was also called heparin. This water-soluble heparin was clinically used and commercially produced. However, due to impurities, its medical use was limited for its adverse reactions, including headaches, fever, and nausea [1, 2].

In 1929, Charles Best, with a graduate student Arthur Charles purified heparin. In 1937, the saline solution of purified heparin was used for the first time in humans, which showed no toxicity while significantly increasing the clotting time. Arthur Charles continued the research and in 1933, along with his colleague David Scott developed a protocol for isolating and purifying heparin from the bovine liver. In 1935, Swedish physiologist J. Erik Jorpes resolved the structure of heparin to allow its commercial production for intravenous use. By 1949, Peter Moloney and Edith Taylor established the low-cost, high-yield method to produce heparin and thus contributed to its widespread availability and use [2]. Between the late 1970s and early 1980s, the LMWHs (MW 4 to 5 kDa) were developed by depolymerization of UFH (MW 12–16 kDa), which opened a new door to the prevention and treatment of VTE [3].

The discovery of warfarin was based on a natural compound from sweet clover (*Melilotus alba* and *Melilotus officinalis*) in the 1920s, when cattle and sheep glazed on its moldy hays in the damp climate on the prairies of Canada and North America showed fetal hemorrhagic disorders. Karl Link, a biochemist, and his colleagues analyzed the unclotted blood of the dead animals. After 6 years of research, they identified and isolated the active compound to be coumarin's oxidation product, dicoumarol (3'-methylene-bis(4-hydroxycoumarin)).



Due to the slow action of dicoumarol, Link expanded the research on coumarin derivatives funded by the Wisconsin Alumni Research Foundation (WARF), and discovered a potent compound in 1945, which he named 'warfarin' after the funding agency and marketed it in 1948 as a rodenticide. Warfarin was marketed as an oral anticoagulant under the trade name Coumadin[®] in 1954 and its mechanism of action was revealed in 1978 to be a disruptor of vitamin K metabolism by inhibiting VKOR [4]. In 1960, a combination of heparin and vitamin K antagonist (dicoumarol) was found to be effective in the treatment and prophylaxis of VTE, which markedly reduced the risk of death and recurrence of PE [5].

The 1960s marked the era of the discovery of antiplatelet properties of aspirin. In 1975, the mechanism of action of aspirin was determined by scientists from Washington University at St. Louis. Later in the 1980s and 1990s, the anti-adenosine diphosphate (ADP) agents (*e.g.*, ticlopidine and clopidogrel) as well as GPIIb/IIIa receptor antagonists (*e.g.*, abciximab) were developed as clinically effective antiplatelet agents. The search for more selective and convenient anticoagulants continued by specifically targeting factor Xa and thrombin. Fondaparinux, a parental pentasaccharide anticoagulant targeting factor Xa (approved by the U.S. Food and Drug Administration (FDA) in 2001), and ximelagatran, an oral direct thrombin inhibitor (never received FDA approval for use due to hepatotoxicity) provided great advantage to both the patients and prescribers in that it could be used in fixed doses without the need for routine monitoring. These agents paved the way for new NOACs class of the latest generation anticoagulants. Dabigatran (Pradaxa[®]) was the first NOAC, a DTI, to get approval from the European Medicines Agency in March 2008, and by the FDA in October 2010 for the prevention of thromboembolic diseases following hip or knee replacement surgery and for non-valvular atrial fibrillation (AF). Later apixaban, edoxaban, and rivaroxaban (factor Xa inhibitors) also got approval for use in the prevention of stroke in patients with AF and the prevention and treatment of VTE [6 - 8]. Today many anticoagulants are frequently appearing in the top 200 most prescribed drug list. Those that occurred in 2019 and 2020 are shown in Fig. (1).

Antihistamines, Proton Pump Inhibitors and Related Drugs

M. O. Faruk Khan^{1,*}

¹ University of Charleston, School of Pharmacy, Charleston, WV, USA

Abstract: This chapter is a comprehensive account of the medicinal chemistry of antihistamines, H₂ receptor (H₂R) blockers, H₃ receptor (H₃R) blockers, and proton pump inhibitors (PPIs). It provides the mechanism of drug action and detailed structure-activity relationship (SAR) of the drugs in these classes to give the knowledge base for pharmacists. After studying this chapter, students will be able to:


- Describe the physicochemical properties of histamine and histamine receptors.
- Identify chemical classifications and describe the SAR of antihistamines, H₂R and H₃R antagonists.
- Differentiate receptor binding patterns and structural features between histamine receptor agonists and antagonists.
- Distinguish between sedating and non-sedating antihistamines, as well as the first-, second- and third-generation antihistamines.
- Describe the structural features of cromolyn and related mast cell stabilizers and their therapeutic applications.
- Discuss the proton pump inhibitors, including their development, mechanism of action, and structural and physicochemical features.
- Apply the medicinal chemistry principles to the clinically relevant case studies.
- Explain the drug discovery story of representative drugs of different classes.

Keywords: Antihistamine, H₂R inhibitors, H₃R inhibitors, Histamine, Mast cell stabilizers, Proton pump inhibitors, Structure-activity relationship, SAR.

* Corresponding author M. O. Faruk Khan: University of Charleston, School of Pharmacy, Charleston, WV, USA; Tel: 304-357-4860; E-mail: mdomarkhan@ucwv.edu

HISTORICAL BACKGROUND

An excellent account of the history of anaphylaxis, histamine, and antihistamine has been published by Emanuel [1]. Numerous studies have been conducted to understand the physiological and cellular mechanisms of the anaphylaxis and allergic reactions, a concept first described as altered reactivity in 1902 [2]. Histamine, a β -imidazolyl ethylamine, was the first biogenic amine in the group of small molecules with potent biological action to be characterized (in 1907) and synthesized by decarboxylation of histidine (in 1910) [3, 4]. During the same time period, Wellcome Pharmaceutical's Dale and Barger isolated ergotoxin from ergot and its decomposition products histamine and acetylcholine. Immediately afterwards they showed that histamine caused constriction of isolated guinea-pig ileum and induced a shock-like syndrome when injected into mammals. Later in 1927, histamine was identified in normal tissues especially in lungs [5 - 7]. Based on these observations, Dale in 1929 postulated that histamine played a major role in anaphylaxis reactions, which was supported by several subsequent observations [8 - 11]. Sir Henry Dale was awarded the Nobel Prize in Physiology or Medicine in 1936 on account of his discoveries relating to chemical transmission of nerve impulses, much of which involved histamine and the histamine receptors.



Histamin

In the 1930s the Pasteur Institute began the search for antihistamines after histamine's role in allergy and anaphylaxis was established [1]. Fourneau and Bovet first reported the antihistaminic properties of certain phenolic ethers in 1933. During the Second World War in the early 1940s, both France and North America separately continued the search for an antihistaminic agent for clinical use. Fig. (1) illustrates the structures of a few antihistamines developed during the 1940s [1]. 2-Isopropyl-5-methyl phenoxyethyl diethylamine (**1**) was the most effective of these compounds but was not used clinically due to toxicity [12]. Changing the substitution in the benzene ring furnished a new compound (**2**) with potent antihistaminic potency but had toxicity [13]. Antergan (**3**, phenbenzamine) was patented by Rhone Poulenc in 1941, and was the first antihistamine used clinically in men [14]. By 1950, about 20 antihistamines were available for clinical use including diphenhydramine and promethazine (Phenergan[®]) [1].




Fig. (1). A few historic antihistamines developed during the 1940s.

Antihistamines rapidly entered into clinical practice and became the drugs of choice for the treatment of various allergic disorders, particularly rhinitis, conjunctivitis, and urticaria. However, a major drawback was sedation and the search for nonsedating antihistamines became a major goal of the pharmaceutical industries. After about four decades of research, the nonsedating antihistamines astemizole and terfenadine were introduced in the 1980s [1].

Because the antihistamines available in 1962 inhibited some but not all the actions of histamine, working on histamine agonists, it was suggested that there had to be more than one histamine receptor. The term H_1 receptor was proposed by Ash and Schild in 1966 to understand the mechanism of action of antihistamines. Some activity of histamines including stimulation of isolated gastric secretion, inhibition of rat uterine contraction, and stimulation of isolated atria were not blocked by these antihistamines, which were proposed to be mediated through H_2 receptors (H_2R) [15]. The existence of H_2R were confirmed by Black *et al.* in 1972 with the synthesis of burimamide as a selective H_2 blocker [16]. Over the last three decades, two additional histamine receptors, H_3 and H_4 , have been characterized. The human H_1 receptor was cloned in 1993 and its polymorphism described in 1998. The cloning of the human H_2 , H_3 and H_4 receptors were completed in 1991, 1999, and 2000, respectively [17, 18].

During 1960s, a subdivision of AstraZeneca R&DTM started a research project to find drugs capable of inhibiting gastric acid secretion for use in patients with

Diabetes and Antidiabetic Drugs

M. O. Faruk Khan^{1,*}

¹ University of Charleston, School of Pharmacy, Charleston, WV, USA

Abstract: This chapter is a comprehensive account of diabetes and the medicinal chemistry of antidiabetic drugs. It provides the mechanism of disease progression and drug action and detailed structure-activity relationships (SAR) of antidiabetic drugs to give the knowledge base for pharmacists. After studying this chapter, students will be able to:

- Discuss the epidemiology and etiology of diabetes.
- Describe the clinical features of diabetes and differentiate between type I and type II diabetes.
- Discuss various risk factors and corresponding mechanisms responsible for the development of diabetes.
- Review biosynthesis of insulin, its metabolic outcomes, regulation of insulin secretion, and insulin signaling.
- Explain in detail the pathophysiologic mechanisms responsible for the clinical features of diabetes.
- Evaluate the clinical role of natural human insulin and commercially available other insulin products and discuss its mechanism of action, pharmacokinetics, adverse effects, motor complications, drug interactions, contraindications, and precautions.
- Discuss the mechanism of action, pharmacokinetics, adverse effects, motor complications, drug interactions, contraindications, and precautions for each class of antidiabetic drugs listed below.
 - o Sulfonylureas: tolbutamide (Orinase[®]), tolazamide (Tolinase[®]), chlorpropamide (Diabinese[®]), and acetohexamide (Dymelor[®]), glyburide (Diabeta[®]), glipizide (Glucotrol[®]), and glimepiride (Amaryl[®]).
 - o Meglitinides: repaglinide (Prandin[®]), nateglinide (Starlix[®]).
 - o Biguanides: metformin (Glucophage[®], Glucophage XR).

* Corresponding author M. O. Faruk Khan: University of Charleston, School of Pharmacy, Charleston, WV, USA; Tel: 304-357-4860; E-mail: mdomarkhan@ucwv.edu

- o Peroxisome proliferator activated receptor (PPAR) agonists/Thiazolidinediones: pioglitazone (Actos[®]), rosiglitazone (Avandia[®]).
- o Alpha glucosidase inhibitors: acarbose (Precose[®]).
- o Glucagon-like peptide-1 (GLP-1) agonists: dulaglutide (Trulicity[®]), exenatide (Bydureon[®], Byetta[®]), liraglutide (Victoza[®]), lixisenatide (Adlyxin[®]), semaglutide (Ozempic[®], Rybelsus[®]).
- o Dipeptidyl peptidase-4 (DPP-4) inhibitors: alogliptin (Nesina[®]), linagliptin (Tradjenta[®]), saxagliptin (Onglyza[®]), sitagliptin (Januvia[®]).
- o Amylin agonist: pramlintide (Symlin[®]).
- o Sodium-glucose cotransporter-2 (SGLT2) inhibitors: empagliflozin (Jardiance[®]), canagliflozin (Invokana[®]), dapagliflozin (Farxiga[®]), ertugliflozin (Steglatro[®]).
- o Miscellaneous agents.

Keywords: Diabetes mellitus (DM), Antidiabetic drugs, Insulin, Biguanide, Insulin receptor (IR), Metformin, Sulfonylureas, Structure-activity relationship, SAE and drug-receptor.

HISTORICAL BACKGROUND

Although anti-diabetic medication has been known since the prehistoric era, the real breakthrough came in the early twentieth century with the discovery of insulin and biguanides. Table 1 shows the milestones of the discovery of anti-diabetic drugs since the early twentieth century [1]. Dr. Frederick Banting, a surgeon and World War I veteran, became interested in diabetes and was able to extract a substance from canine pancreatic glands. By December 1921, Banting and his student, Charles Best, extracted insulin by combining equal parts of the ground beef pancreas and slightly acidic alcohol. The extracted solution (insulin) was filtered, washed with toluene, sterilized, and given to dogs. Leonard Thompson, a 14-year-old concentration camp victim with diabetic ketoacidosis, was the first patient to receive this insulin solution. On 11 January 1922, a young house officer, Ed Jeffery, injected 7.5 ml of this extract into his buttock which dropped his blood glucose. Banting's team signed an agreement with Eli Lilly Pharmaceuticals and by July 1922, Banting received the first bottle of Lilly's Iletin (insulin). Insulin was commercially available in the United States by 1923. In 1926, the technique for crystallization of insulin was discovered that led to the purer soluble (regular) insulin and opened the door to modified insulin formulations with different time-action profiles. The first commercially available PZI (protamine zinc insulin) with an extended duration of action was released in 1936. Within 10 years, Nordisk Insulin Laboratory in Denmark released NPH

(Neutral Protamine Hagedorn), which has a shorter duration than PZI, but can be combined with regular insulin. The lente insulin series was introduced in 1956. The first recombinant insulin was approved in 1983 (before that all insulins were derived primarily from beef and pork). Insulin lispro, the first rapid-acting human insulin analog, was approved in 1996. The next 15 years added quick and long-acting analogs, including insulins aspart, glulisine, glargine and detemir. The ultra-long-acting insulin degludec (duration of 42 hours) was approved in Europe in 2013 when the U.S. Food and Drug Administration (FDA) declined to approve it; however, it was approved by FDA in 2015 after resubmission. Better formulations as well as techniques for the delivery of insulin have been developed over the years [1].

Table (1). Milestones in antidiabetic medications.

Year	Milestone
1915 early 1920s	Discovery of guanidine from <i>Galega officinalis</i> and synthesis of Synthalin
1922	First insulin administered to a human
1923	Insulin (Iletin) commercially available in the US
1936	PZI Insulin
1946	NPH Insulin
1956	First commercially available sulfonylurea in the US; Lente insulins introduced
1959	Metformin introduced in Europe (1990s in the US)
1983	Recombinant human insulin
1984	Second generation sulfonylureas
1995	First AGI (acarbose)
1996	First TZD (troglitazone)
1997	First meglitinide (repaglinide)
2005	First amylin agonist (pramlintide) First GLP-1 receptor agonist (exenatide)
2006	First DPP-4 inhibitor (sitagliptin)
2008	Colesevelam
2009	Bromocriptine
2013	First SGLT2 inhibitor (canagliflozin)

The identification of antihyperglycemic guanidine moiety from the medieval folk remedy of diabetes in Southern and Eastern Europe, *Galega officinalis* (French lilac, or goat's rue), led Frank *et al.* to synthesize Synthalin in Germany in the 1920s. It was in the market to treat diabetes for a short period due to

Hormoneal Therapy

M. O. Faruk Khan^{1,*} and Chelsey Llayton¹

¹ University of Charleston, School of Pharmacy, Charleston, WV, USA

Abstract: Treatments that involve the use of hormones or their antagonists are commonly referred to as hormone therapy or hormonal therapy. Oncologic hormone therapy, hormone replacement therapy (HRT), androgen replacement therapy (ART), oral contraceptive pills and gender-affirming hormone therapy are the major classes of hormonal therapy in addition to a few others. Some hormonal therapies will be discussed in detail under different chapters including oncologic hormone therapy, glucocorticoids and mineralocorticoids and insulin under antineoplastic agents, anti-inflammatory steroids and antidiabetic agents, respectively. After studying this chapter, students will be able to:

- Define and classify hormonal therapy and differentiate between hormonal therapy and treatment.
- Explain all types of hormone replacement therapy including menopausal, androgens, and oral contraceptives.
- Discuss the use of androgen replacement therapy (ART) in males with low levels of testosterone due to disease or aging.
- Describe gender-affirming hormone therapy such as feminizing hormone therapy and masculinizing hormone therapy.
- Identify appropriate growth hormone therapy for growth hormone deficiency.
- Demonstrate understanding of thyroid hormone replacement in hypothyroidism and antithyroid therapy in hyperthyroidism.
- Demonstrate clear guidance to the use of oral contraceptive pills for various purposes including birth control.

Keywords: Breast cancer, Cardiovascular disease, Contraceptives, Hormone replacement therapy, Osteoporosis, Thyroid hormone (TH), Thyroid receptor (TR).

* Corresponding author M. O. Faruk Khan: University of Charleston, School of Pharmacy, Charleston, WV, USA; Tel: 304-357-4860; E-mail: mdomarkhan@ucwv.edu

HISTORICAL PERSPECTIVE

Hormone Replacement Therapy

Hormone Replacement Therapy (HRT) began with the isolation of estrogen hormone in the early 20th century by Edward Adelbert Doisy and his colleagues at the St. Louis University Medical School in the urine and follicular fluids of pigs. The first commercial preparation of estrogen called Emmenin, an oral solution for treating dysmenorrhea, was described in 1935 in the *Canadian Medical Association Journal*. Its commercial preparation began as an estrogen complex extracted from placentas. Within a few years, Premarin[®] was commercially manufactured from the urine of pregnant mares, and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of menopausal hot flashes. Premarin[®] is a combination of at least ten estrogens, with estrone being the dominant one [1].

The real significance of HRT started in the 1960s with the feminist movement. In 1966, Wilson published the bestseller book “Feminine Forever” claiming that menopause is a hormone deficiency disease that is curable and preventable by estrogen. However, it was found in the 1970s that conjugated estrogen therapy may lead to the development of endometrial cancer, a risk that can be lowered by reducing the dose of estrogen and combining it with progesterone. By 1988, HRT comprising estrogen and progesterone received an FDA approval for the treatment of both hot flashes and osteoporosis. It was later found to be beneficial for many other chronic diseases including cardiovascular conditions of postmenopausal women. This greatly increased the popularity of HRT in the 1990s. Their marketing efforts brought Premarin[®] as the No. 1 prescribed drug in the United States (U.S.) by 1992. By 1997, its sales exceeded \$1 billion [1, 2]. In 1998, the Women’s Health Initiative (WHI) started the largest clinical trial on HRT and chronic postmenopausal conditions in the U.S. using the combination drug PremPro. The first negative results were announced in 2002 receiving wide publicity and showing that the risks outweighed the benefits of HRT leading to a drop in HRT use. However, no distinction was made between the synthetic and natural hormones which was considered to be a major flaw of the study [2]. Nevertheless, HRT remained an effective treatment for menopausal hot flashes and vaginal dryness with individualized treatment plans from their doctors to minimize the risk. It is thought that relatively younger women (<60 years old) whose menopausal transition took place in less than 10 years may benefit the most from HRT [1].

Another study on the use of testosterone in menopausal women was conducted in 2004 by researchers in Australia administering testosterone pellets underneath the

skin. When testosterone was taken in combination with traditional HRT, it remarkably reduced the incidence of breast cancer in addition to improving the common symptoms of menopause. In 2013, after a 10-year study conducted in the U.S., it was found that testosterone alone improved all symptoms of menopause, including hot flashes, sleep disorder, depression, irritability, anxiety, physical or mental exhaustion, sexual and bladder problems, vaginal dryness, and joint and muscular discomfort, and also substantially (50-70%) reduced breast cancer incidences. No major adverse effects were noticed. A study carried out in 2017 also showed remarkable results in treating stage II breast cancer in combination with chemotherapy and follow-up surgery [3]. However, testosterone is not FDA-approved for widespread use in women. Studies of longer durations are needed to establish the safety and effectiveness for women before its use will become popular.

Oral Contraceptives

Margaret Sanger, who opened the first birth control clinic in America in 1916, pioneered the age-old quest for safe and effective oral contraception in the middle of the 20th century. Sanger, along with her strong collaborator and donor Katharine Dexter McCormick, were the advocates and financial supporters in the efforts to develop an oral contraceptive. In 1953, they financed the contraceptive research of Gregory Pincus and Min Chueh Chang of the Worcester Foundation for Experimental Biology in Massachusetts, who were trying to produce an oral contraceptive based on synthetic progesterone. Sanger and McCormick established Planned Parenthood's research grant program based mostly on donations from McCormick. The basic research of contraceptive development was also largely supported by Russell Marker's discovery of progestin in Barbasco root that had been eaten by generations of Mexican women for contraception. Gregory Pincus combined progestin with estrogen to formulate the first birth control pill. The first clinical trials of the pill were conducted by Dr. John Rock and funded by McCormick. They were conducted in Puerto Rico due to challenges including issues from the Catholic church, Massachusetts law (it was illegal to conduct a contraceptive trial), and the mobility of post-World War II American women of reproductive age. The trials began in April 1956 and the FDA approved the use of the pill to regulate menstruation in 1957. It had a package insert with a warning about its contraceptive activity. After facing critiques and inherent drawbacks of the trials at that time, it was finally successful in receiving FDA approval as an oral contraceptive on June 23, 1960, with the brand name Enovid. The pill was manufactured by G.D. Searle and Company which also supported its basic research for many years. The 1960s also observed sexual revolution and established family planning as the cultural norm. Modern oral contraceptives contain dramatically lower concentrations of both progestin

CHAPTER 8**The Prostanoids****M. O. Faruk Khan^{1,*} and Karrie Murphy¹**¹ *University of Charleston, School of Pharmacy, Charleston, WV, USA*

Abstract: This chapter is a comprehensive account of the medicinal chemistry of drugs arising from structural modifications of prostanoids, which are naturally occurring eicosanoids. These drugs are used for a variety of diseases including but not limited to glaucoma, pulmonary arterial hypertension, and peptic ulcers. This chapter provides the mechanism of drug action and structure-activity relationships (SAR) of these drugs. After studying this chapter, students will be able to:

- Describe the historical background of prostanoids as clinical agents.
- Explain the structure, functions, classifications and biosynthesis of eicosanoids.
- Discuss in detail the chemistry and SAR of the prostanoids involved in the treatment of glaucoma, pulmonary arterial hypertension, peptic ulcer, and other diseases.
- Delineate the clinical significance and therapeutic evaluations of these classes of drugs by solving case studies.
- Explain the discovery process of latanoprost and zafirlukast.

Keywords: Prostaglandins, Prostacyclin, Pulmonary arterial hypertension (PAF), Glaucoma, Structure-activity relationship (SAR), Drug receptor interaction, Intraocular pressure.

HISTORICAL BACKGROUND

In the 1930s, gynecologists at Columbia University in New York published their finding of uteri undergoing artificial insemination and occasional contraction and relaxation. This observation led Ulf von Euler at the Karolinska Institute in Stockholm to discover an acid from extracts of monkey, sheep, and goat seminal vesicles. He named the acid prostaglandin (PG), which lowered blood pressure and caused contraction of smooth muscles. Later along with his student, Sune Bergström, he established PG to be free of nitrogen. In the 1950s, Bergström's

* **Corresponding author M. O. Faruk Khan:** University of Charleston, School of Pharmacy, Charleston, WV, USA; Tel: 304-357-4860; E-mail: mdomarkhan@ucwv.edu

team isolated and elucidated the structures of several highly potent PGs through grant support from the Upjohn Company. Based on the pattern of the cyclopentane ring in those PGs, he classified those as types A to F with a subscripted number to indicate the number of unsaturated centers in the side chains. He also used suffix α or β to indicate the stereochemical configuration of ring substituents. He isolated crystals of alprostadil (also known as PGE₁) from sheep prostate glands in 1957. Within five years he also isolated dinoprost (or PGF_{2 α}) and dinoprostone (or PGE₂) as highly potent mammalian PGs.

Phillip Beal and his colleagues first synthesized the natural PG in the Upjohn laboratories in 1965. Within the next five years PGE₁, PGE₂ and PGF_{2 α} were also synthesized by different scientists and laboratories. These three PGs were proven to be clinically significant among sixteen naturally occurring PGs. However, the PGEs bearing a β -hydroxy carbonyl in the cyclopentane ring readily undergo an acid or base-catalyzed elimination reaction [1]. Collectively, all these bioactive natural compounds arising from 20-carbon fatty acids are known as *eicosanoids*.

The report in 1967 that a few PGEs inhibited gastric acid secretion was intriguing in the treatment of peptic ulcer but was found inactive by mouth due to oxidative metabolism of the 15-hydroxyl group present in the side chain. The vasodilating properties of PGE₁ have been exploited in neonatal congenital heart diseases. PGE₂ has been exploited for its ability to contract the uterus for inducing abortion. Epoprostenol has been found beneficial in kidney transplantation surgery as an alternative to heparin in patients at high risk of bleeding. They act *via* receptor-mediated G-protein linked signaling pathways [1]. Today, numerous prostanoids and their derivatives are employed in clinical practices for a variety of diseases including glaucoma, pulmonary arterial hypertension (PAH) and peptic ulcers. In modern clinical practice, the commonly used prostanoids are either the analogs of PGs, prostacyclin (PGI₂), or leukotrienes (LT) and a number of these frequently appear in the top 200 drug list, which are shown in Fig. (1).

INTRODUCTORY CONCEPTS

Eicosanoids: Structure and Function

Fig. (2) shows the structures of all types of prostanoids and prostanoid acids. Prostanoids are eicosanoids derived from 20-carbon fatty acids especially arachidonic acid by oxygenation. These are messenger lipids, produced in almost all cells except red blood cells. *Four principal types* of eicosanoids are: prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs) and lipoxins (LXs). The PGs and TXs are collectively known as prostanoids which are commonly used in clinical practice. PGs have a characteristic oxygenated cyclopentane ring formed by a connection between the C₈ and C₁₂ of an

arachidonic acid precursor and commonly possess a trans double bond between C₁₃ and C₁₄. Usually, C₉ and/or C₁₁ is/are oxygenated *via* a keto or hydroxyl function and C₁₅ is hydroxylated in different PGs. The PG analogs containing additional endocyclic oxygenated ring system are known as prostacyclin (or PGI₂). In TXs, the cyclopentane ring has been replaced with a six-membered oxygen-containing ring (termed an *oxane*). The LTs contain a conjugated triene system.




Fig. (1). Frequently prescribed prostanoid analogs.




Fig. (2). Structures of all prostanoids and prostanoid acid.

SUBJECT INDEX

A

- Acid(s) 33, 77, 84, 87, 114, 129, 147, 148,
191, 193, 197, 198, 237, 239, 250, 255,
261, 264, 284, 289, 353, 354, 359, 360,
361, 362, 363, 364, 366, 369
- acetic 129
- acetylsalicylic 129
- amino isobutyric 264
- benzoic 250
- bimatoprost 362
- carbonic 77
- carboxylic 191
- ethacrynic 84, 87
- glucuronic 114, 147
- glutamic 237, 284
- lactic 255
- latanoprost 359, 360, 361
- monocarboxylic 369
- myristic 239
- palmitic 261
- peptic disorders 198
- prostaglandin 353
- salicylic 129
- sulfenic 197
- tranexamic 147, 148
- Acidosis 74, 77, 95, 99, 101, 255
- lactic 255
- metabolic 74, 77, 95
- systemic 99, 101
- Activation 33, 131, 132, 135, 136, 140, 142,
163, 198, 199, 230, 234
- proteolytic 142
- Activity 49, 53, 55, 56, 57, 58, 77, 81, 85, 88,
96, 98, 100, 135, 137, 144, 172, 180,
182, 186, 187, 188, 208, 209, 233, 247,
252, 257, 281, 316, 320, 323, 333, 343,
365
- adenylate cyclase 137
- androgenic 316
- anti-breast cancer 323
- anti-inflammatory 257
- anti-platelet 135
- antiarrhythmic 247
- anticholinergic 172
- antidiabetic 252
- antidiuretic 100
- antidopaminergic 186
- antileukotriene 188
- antineoplastic 320
- antiplatelet 137
- antipsychotic 187
- antiserotonergic 180
- diuretic 81, 85, 96, 98
- glucocorticoid 343
- oxytocic 365
- serotonergic 182
- tyrosine kinase 233
- Acute 121, 131, 132, 134, 135, 142, 143, 200,
207
- coronary syndrome (ACS) 121, 131, 132,
134, 135, 200
- ischemic strokes 142, 143
- toxicity 207
- Adenosine 136, 150, 358
- deaminase 136
- triphosphate 150, 358
- ADP 136, 200
- function 136
- inhibitory effects 136
- mediated platelet aggregation 200
- Adverse drug reaction (ADR) 81, 85, 87, 89,
92, 107
- Agents 61, 107, 129, 145, 182, 195, 209, 278,
291, 295, 299, 317, 319, 364, 376
- anti-obesity 195
- anti-progesterone 317
- antianginal 61
- antifibrinolytic 145
- antihyperglycemic 291
- antineoplastic 295, 299, 319
- antipruritic 182
- antipyretic 129
- antiulcer 364, 376
- fibrinolytic 107
- histaminergic 209
- hypolipidemic 278

Subject Index

Allergic 117, 118, 123, 141, 143, 161, 162, 165, 184, 195, 201, 202, 264, 330, 356, 369
disorders 162
reactions 117, 118, 123, 141, 143, 161, 165, 202, 264, 330, 356
rhinitis 184, 195, 201, 369
Allergies, ophthalmic 191
Alzheimer's disease 195
AMP-activated protein kinase 253, 254
Anabolic 298, 326, 327, 328
androgenic steroids (AAS) 326
effects 298, 326, 328
steroids 298, 327
Anaphylactic reactions 143
Androgen replacement therapy (ART) 295, 298, 299, 301, 311, 343
Androgenic 316, 324, 325, 326, 349
agents 324, 325
effects 326, 349
properties 316
Anemia 125, 257, 327
hypoplastic 327
Angiogenesis, promoting 318
Angiotensin converting enzyme (ACE) 1, 2, 3, 5, 6, 8, 9, 10, 11, 22, 23, 25, 26, 27, 28, 30, 31, 34, 35
inhibitors (ACEIs) 1, 2, 3, 5, 6, 8, 9, 10, 22, 23, 25, 30, 31, 34, 35
Angiotensin inhibition 3
Anti-inflammatory steroids 295, 299
Anti-thyroid agents 331
Antiandrogenic action 193
Anticholinergic 172, 175, 178, 180, 182, 184, 187
effects 172, 182
Anticoagulant(s) 107, 108, 109, 111, 117, 118, 120, 123, 124, 125, 126, 143, 144, 150, 152
action 117, 120, 123, 124, 126, 144, 150
drugs 111, 143, 152
properties 108, 118, 143
oral 107, 109, 118, 125, 150
Antidiabetic agents 223, 224, 250, 259, 260, 261, 263, 264, 265, 268, 270, 271, 272, 274, 275, 278, 279, 290, 295
additional oral 275
oral 250, 260, 263, 265, 274, 278
Antihistamine action 162, 169
Antihypertensive 2, 5, 18, 31, 32, 50, 52, 90

Medicinal Chemistry for Pharmacy Students, Vol. 3 383

agents 2, 5, 18, 31, 50
effects 5, 18, 32, 52, 90
Antinausea products 176, 208
Antiplatelet 109, 132, 134, 136, 201
action 132, 134
properties 109, 136
therapy 201
Antipsychotic action 187
Antithrombotic drug discovery 151
ATP 196, 241
binding cassette (ABC) 241
hydrolysis 196
Attention deficit hyperactivity disorder (ADHD) 195

B

Biosynthesis 3, 227, 304, 311, 313, 331, 332, 335, 344, 353, 356, 357
glucocorticoid 313
of progesterone 311
of prostaglandins 356
Blood 112, 113, 114, 127, 131, 134, 144, 366
clotting 113, 114, 131, 134
coagulation 112, 113, 127, 144
flow, systemic 366
Blood pressure (BP) 1, 3, 18, 21, 23, 24, 25, 52, 53, 60, 61, 62, 90, 93, 272, 273
diastolic 272, 273
Body mass index (BMI) 261, 339, 340
Bradykinin potentiating factor (BPF) 2
Brain cancer 141
Breast cancer 295, 297, 310, 322, 325, 342

C

Carbonic anhydrase inhibitor (CAIs) 70, 76, 77, 79, 81, 95, 96, 98, 99, 102, 103
Carboxylate metabolite 16
Carboxylesterase 127, 132, 368
hepatic 368
Cardiovascular 296, 333
conditions 296
System 333
Cerebral vascular lesion 141
Chemical 70, 161
metabolites 70
transmission 161
Cholecystectomy 310

Cholecystitis 310
 Cholelithiasis 310
 CNS depressant effects 177, 183
 Coactivators, pro-inflammatory 256
 Colonic distress 258, 283
 Combination therapy 22, 184, 203, 250, 255
 Configuration, stereochemical 354
 Conjunctival hyperemia 361, 373
 Conversion, thrombin-induced 123
 Coronary 62, 123, 130
 angioplasty 123, 130
 vasodilating effect 62
 Cytotoxicity 262

D

Decomposition, gastric acid 200
 Deep vein thrombosis (DVT) 114, 126, 127, 148
 Defects, congenital heart 366
 Depression, cardiac 61
 Diabetes 221, 223, 224, 225, 227, 228, 229, 230, 231, 251, 253, 271, 273
 Cystic fibrosis-related 227
 ketoacidosis 231
 mellitus (DM) 221, 223, 224, 225, 227, 228, 229, 230, 231, 271, 273
 ketoacidosis 221, 231, 251, 253
 syndromes 227
 Diarrhea and abdominal pain 364
 Direct thrombin inhibitor (DTIs) 107, 109, 121, 122, 123, 151, 152, 153
 Diseases 42, 43, 45, 60, 74, 93, 94, 109, 114, 131, 137, 151, 165, 195, 198, 226, 227, 270, 295, 296, 306, 310, 334, 353, 354, 369
 atherosclerotic 270
 atherosclerotic cerebrovascular 137
 cardiovascular 295, 306, 310
 chronic 226, 296
 chronic obstructive pulmonary 60, 94
 congenital heart 354
 coronary artery 226
 gastroesophageal reflux 93, 198
 infectious 334
 inflammatory 165, 195
 ischemic heart 45
 neurodegenerative 43
 renal 131
 thromboembolic 109

 thrombotic 151
 Disorder 112, 226
 autoimmune 226
 Disseminated intravascular coagulation (DIC) 112
 DNA 256, 318
 technology 318
 Dyslipidemia 261
 Dyspareunia 306
 Dyspepsia 128, 196, 263

E

Edema, cerebral 247
 Effects 87, 129, 135, 172, 182, 207, 253, 265, 272, 317, 325, 364
 antihistaminic 172, 182
 antihyperglycemic 253, 272
 antineoplastic 325
 antiprogestational 317
 antisecretory 207, 364
 antithrombotic 129
 cardiovascular 135
 hematologic 87
 immunomodulatory 265
 Embolism 107, 112, 116, 124, 150
 pulmonary 107, 116, 150
 Endothelium-derived relaxation factor (EDRF) 50
 Enzyme 59, 63, 142
 hepatic microsomal 59
 metabolic 63
 thrombolytic 142
 Estrogen(s) 42, 189, 296, 297, 298, 299, 301, 302, 303, 304, 305, 306, 307, 308, 310, 311, 313
 replacement therapy (ERT) 310
 synthetase 305
 therapy 310
 biosynthesis of 304, 305
 inhibiting 311
 nonsteroidal 310
 Exocytosis 42, 189

F

Factors 256, 306, 332
 transcription 306, 332
 tumor necrosis 256

Fetal hemorrhagic disorders 108
Fibrin 110, 111, 113, 116, 123, 131, 142, 151
 binding 131
 clot formation 151
Fibrinolysis 113, 142
Follicle stimulating hormone (FSH) 301, 303,
 304, 307, 310, 317, 318, 320, 321, 322,
 323

G

Gastric inhibitory peptide (GIP) 229, 230,
 259, 265, 285
Gastrointestinal 87, 130, 163, 191, 201, 229,
 281, 290, 338, 365
 absorption 338
 hemorrhage 130
 hormones 229, 281, 290
 motility 163, 191
Glomerular filtration rate (GFR) 83, 153, 271,
 273, 276
Glucagon secretion 223, 263, 265
 inhibiting 223
 reducing 263
Gluconeogenesis 233, 253, 274, 291
Glucose 227, 229, 230, 231, 233, 253, 260,
 274
 homeostasis 227, 230
 metabolism 233, 253
 stimulated insulin secretion (GSIS) 274
 tolerance 231, 260
 transport 229
Glucosidase 258
Glucosuria, renal 277
Glucuronidation 13, 14, 181, 184, 272, 273,
 313, 315, 362, 363, 367
Glucuronidation enzymes 147
Glucuronide transferase 369, 378
Growth hormone 231, 295, 302, 328, 329
 deficiency 295
 inhibiting hormone (GHIH) 328
 releasing hormone (GHRH) 328
 therapy 302

H

Heart 3, 19, 22, 71, 83, 87, 90, 94, 114, 142,
 227, 255
 disease 227

 failure 3, 19, 22, 71, 83, 87, 90, 94, 114,
 142, 255
Hematopoietic cell transplantation (HCT) 143
Hemodialysis 121
Hemodynamic effects 14
Hemostasis 110, 111, 140, 152
Heparin poisoning 118
Hepatic disease 240, 255
Hepatotoxicity 70, 109, 223, 257, 327
High-density lipoprotein (HDL) 227, 231, 325
Hormonal therapy 295, 299
Hormone(s) 114, 295, 296, 298, 299, 301,
 302, 306, 310, 311, 315, 319, 338, 344,
 346
 deficiency disease 296
 parathyroid 338
 replacement therapy (HRT) 114, 295, 296,
 299, 302, 306, 310, 311, 315, 344, 346
 therapy 295, 298, 299, 301, 302, 319
Hydrolysis, peptidase 234
Hypertension 22, 24, 70, 72, 82, 85, 87, 90,
 92, 93, 138, 143, 255, 261
 pulmonary 138, 143
Hyperthyroidism 24, 295, 302, 334, 336, 344,
 345
Hypoglycemia 240, 248, 252, 263, 269, 270,
 273, 277, 279, 282
 postprandial 270
Hypoglycemic toxicity 279
Hypokalemia 74, 81, 85, 87, 94, 346
Hyponatremia 74, 81, 85
 surgery-induced 74
Hypoprothrombinemia 337

I

Inflammation, leukotriene-mediated 369
Inhibitors 8, 9, 26, 107, 108, 109, 124, 125,
 126, 129, 150, 151, 160, 221, 231, 266,
 301, 325
 aromatase 325
 protease 231
 reductase 301
Insomnia 147, 196, 367
Insulin 229, 240, 250, 277, 285, 329
 activity 285
 fast-acting 240
 glucagon drugs 329
 matured 229
 therapy 250, 277

Ischemia, myocardial 257
Ischemic stroke 126, 141, 144, 200

K

Kawasaki disease 129, 130
Kidney diseases 126, 250

L

Lipoxygenases 357
Liver disease 118, 123
Low 107, 108, 114, 115, 116, 117, 118, 148,
154, 157, 224, 327
density lipoprotein (LDL) 224, 327
molecular weight heparin (LMWHs) 107,
108, 114, 115, 116, 117, 118, 148, 154,
157
Luteinizing hormone (LH) 301, 303, 310, 314,
317, 318, 319, 320, 321, 322, 323

M

Medications 142, 145, 221, 222, 230, 231,
232, 261, 264, 269, 275, 334, 335, 341,
343, 363, 373
anti-diabetic 221
anti-glaucoma 373
antidiabetic 222, 232, 275
Medullary thyroid carcinoma 263
Megakaryocytes 145
Menopausal hormone therapy (MHT) 299,
301
Metabolic 13, 91, 114, 367
oxidation 367
reactions 91
syndrome 114
transformation 13
Metabolism 21, 53, 54, 59, 74, 76, 86, 87, 90,
130, 140, 150, 193, 200, 229, 308, 316,
354, 361, 365
intestinal 200
of aspirin 130
of estrogens 308
oxidative 193, 354
Metabolites 53, 54, 56, 91, 134, 138, 139, 146,
181, 182, 183, 269, 272, 289, 323, 336,
377
alcoholic 183

glucuronide 336
oxidative 377
toxic 336
Metabolizing enzyme 136
Metallopeptidases 7, 26
Mineralocorticoid receptor antagonists (MRA)
87
Mutagenesis 47
Myelofibrosis 327
Myocardial 119, 131, 133, 137, 139, 141, 200
infarction (MI) 119, 131, 133, 139, 141,
200
perfusion imaging 137

N

Nasal congestion 195
Nasopharyngitis 268
Nateglinide therapy 252
Nepriylsin inhibitors 3, 19, 22
Neurological disorders 77
Neurons 41, 163, 165, 247
histaminergic 165
Noncompetitive antagonists 16

O

Oncologic hormone therapy 295, 299
Oral hypoglycemic agents 230, 240, 244, 248,
257, 268, 269, 279, 280, 288, 291
Osteoclast activity 338
Osteoporosis 77, 117, 118, 275, 276, 295, 296,
299, 327, 330, 338
Oxidation 149, 255
anaerobic 255
fungal 149
Oxygen, endocyclic 366

P

Pancreatitis 261, 263, 269
necrotizing 261
Pathways 25, 111, 112, 113, 134, 144, 152,
180, 334, 356, 357, 374
biochemical 25, 111, 112
fibrinolytic 113, 152
lipoxygenase 357
lipoxigenase 356
metabolic 134, 334

Peptic ulcer disease 163, 207
Peptides, gastric inhibitory 229, 230
Peripheral artery disease (PAD) 114, 139
Phenothiazine derivatives 203
Plasma insulin concentrations 241
Platelet 110, 127, 129, 130, 132, 137, 139,
150, 184, 353, 366, 368
 activating factor (PAF) 184, 353
 aggregation 110, 127, 129, 130, 132, 137,
 139, 150, 366, 368
Prader-Willi syndrome 330
Pregnancy, singleton 313
Proinflammatory cytokines 268
Propranolamines 182, 184
Properties 50, 89, 161, 178, 186, 207, 306,
326, 356
 anti-inflammatory 356
 anti-progestogenic 326
 antiandrogenic 89
 antihistaminic 161, 186
 antipsychotic 178
 antisecretory 207
 metabolic 306
Prostate cancer 319, 321
Prostatic 325, 342
 cancer 342
 hyperplasia 325
Proteases, inhibiting 139
Protein 12, 13, 14, 19, 20, 130, 132, 229, 230,
256, 306, 316, 327
 catabolism 327
 glucose-metabolizing 256
Prothrombin time (PT) 121, 156
Pulmonary 138, 337, 353, 354, 359, 366, 367,
368, 372, 374, 377
 arterial hypertension (PAH) 353, 354, 359,
 366, 367, 368, 372, 374, 377
 fibrosis 138
 infiltrates 337

R

Renal dysfunction 255
Reye's syndrome 129
Rheumatoid arthritis 195, 202

S

Sinusoidal obstruction syndrome (SOS) 143

Skin infection 226
Sleep disorder 297
Spironolactone therapy 89
Splenectomy 147
Syndrome 87, 231, 323
 hyperglycemic hyperosmolar nonketotic 231
 nephrotic 87
 ovarian hyperstimulation 323

T

Therapy 230, 295, 310
 antipsychotic 230
 antithyroid 295
 menopausal 310
Thrombocytopenia 118, 122, 128, 130, 145,
337
Thrombocytosis 147
Thromboembolic disorders 126
Thyroid 331, 332, 334, 335, 344
 hormones (THs) 331, 332, 334, 335, 344
 releasing hormone (TRH) 331
 stimulating hormone (TSH) 331, 332
Thyroxine-binding globulin (TBG) 334
Tyrosine kinases 230

W

Warfarin therapy 121, 123, 124, 152, 157

“

Understanding medicinal chemistry is essential for understanding how new drugs are developed and how drugs work in the body. This book is an important contribution to helping students and practitioners deepen their understanding of medicinal chemistry. Of particular note is the integration of clinical content and learning aids for students.

*G. Scott Weston (RPh, MBA, PhD)
Associate Dean for Academic Affairs,
School of Pharmacy, The University of Texas at El Paso
USA*

”

M. O. Faruk Khan

Prof. Dr. Khan is working as a professor of pharmacy at the University of Charleston School of Pharmacy (UCSOP), where he also served as an associate dean for academic affairs and interim dean, leveraging a wealth of experience spanning over 25 years in postdoctoral academic research and teaching across various pharmacy schools. His research expertise encompasses medicinal chemistry, rational drug design, pharmaceutical analyses, organic and peptide synthesis, enzymology, and the scholarship of teaching and learning. Throughout his distinguished career, Dr. Khan has authored over 60 scholarly research articles and served as the primary investigator on numerous research and educational grants. His contributions extend beyond articles to include book chapters in the fields of medicinal chemistry and natural products research. Dr. Khan has assumed diverse leadership roles in professional organizations. He is on the board of American Journal of Pharmaceutical Education. He underscores his commitment to mentorship by advising and guiding numerous pharmacy and graduate students, postdoctoral researchers, and faculty members. Notably, many of his mentees have progressed to become faculty members and scientists at esteemed universities, the US Food and Drug Administration, and research centers around the globe.